NCCN Guidelines® Insights - Management of Immunotherapy-Related Toxicities, Version 2.2024
These NCCN Guidelines Insights highlight recent guideline updates pertaining to the management of emerging toxicities related to cancer immunotherapy.
Category
  • Management of Immunotherapy-Related Toxicities
Format
  • Monograph/Journal Supplement
Credits
  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 Participation
Cost $0.00
CRS and ICANS Management in CAR T/Bispecific Antibody Therapies
As these therapies continue to evolve, it is imperative that nursing policies are created/revised and shared with nursing staff to remain up to date on current clinical practice for these complications. With continued education and reinforcement of protocols, nurses can positively impact patient outcomes.
Category
  • Management of Immunotherapy-Related Toxicities
Format
  • Recorded Webcast
Credits
  • 0.75 ANCC contact hours
  • 0.75 Participation
Cost $0.00
Management of Immune Checkpoint Inhibitor-Related Toxicities
The landscape of cancer care has undergone a dramatic shift, due to the availability and increased use of immunotherapy agents such as immune checkpoint inhibitors (ICIs). As more patients become eligible to receive ICIs, clinicians need to be able to recognize immune-mediated adverse events (irAEs) and remain informed about the most up-to-date strategies for managing these toxicities.
Category
  • Management of Immunotherapy-Related Toxicities
Format
  • Recorded Webcast
Credits
  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 Participation
Cost $0.00